2-(2-chlorophenyl)-4-(4-pyridylamino)-quinazoline

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-(2-chlorophenyl)-4-(4-pyridylamino)-quinazoline
• 英文别名: 2-(2-chlorophenyl)-4-(pyridin-4-ylamino)-quinazoline；2-(2-chlorophenyl)-N-pyridin-4-ylquinazolin-4-amine
• 化学式: C₁₉H₁₃ClN₄
• 分子量: 332.792
• InChiKey: GFAMVEXIOQUVBP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  24
• 可旋转键数：
  3
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  50.7
• 氢给体数：
  1
• 氢受体数：
  4

文献信息

• Method of treating mucus hypersecretion
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20030220336A1

  公开（公告）日：2003-11-27

  The invention relates to the use of p38 kinase inhibitors for the preparation of a pharmaceutical composition suitable for inhalation for the treatment of mucus hypersecretion. Furthermore the invention is directed to pharmaceutical compositions suitable for inhalation comprising p38 kinase inhibitors and to methods for the preparation thereof.

  本发明涉及使用p38激酶抑制剂制备适用于治疗黏液过度分泌的吸入药物组合物。此外，本发明还涉及适用于吸入的含有p38激酶抑制剂的药物组合物以及其制备方法。
• Quinazoline derivatives as medicaments
  申请人：——

  公开号：US20030069248A1

  公开（公告）日：2003-04-10

  The invention is directed to methods to inhibit TGF-&bgr;and/or p38-&agr; kinase using compounds of the formula 1 or the pharmaceutically acceptable salts thereof wherein R 3 is a noninterfering substituent; each Z is CR 2 or N, wherein no more than two Z positions in ring A are N, and wherein two adjacent Z positions in ring A cannot be N; each R 2 is independently a noninterfering substituent; L is a linker; n is 0 or 1;and Ar′ is the residue of a cyclic aliphatic, cyclic heteroaliphatic, aromatic or heteroaromatic moiety optionally substituted with 1-3 noninterfering substituents.

  该发明涉及使用式1化合物或其药学上可接受的盐来抑制TGF-β和/或p38-α激酶的方法，其中： R3是非干扰基； 每个Z是CR2或N，其中环A中不超过两个Z位置是N，且环A中相邻的两个Z位置不能是N； 每个R2是独立的非干扰基； L是连接基； n为0或1； Ar′是循环脂肪族、循环杂脂族、芳香族或杂芳香族残基，可选地被1-3个非干扰基取代。
• Pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：US20040044020A1

  公开（公告）日：2004-03-04

  The present invention relates to novel pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

  本发明涉及基于新型抗胆碱能药物和p38激酶抑制剂的新型药物组合物，其制备方法以及在呼吸系统疾病治疗中的应用。
• Pharmaceutical compositions of anticholinergics and P38 kinase inhibitors in the treatment of respiratory diseases
  申请人：Boehringer Ingelheim Pharma GmbH & Co. KG

  公开号：EP1707205A2

  公开（公告）日：2006-10-04

  The present invention relates to novel pharmaceutical compositions based on novel anticholinergics and p38 kinase inhibitors, processes for preparing them and their use in the treatment of respiratory diseases.

  本发明涉及基于新型抗胆碱能药和 p38 激酶抑制剂的新型药物组合物、其制备工艺及其在治疗呼吸系统疾病中的用途。
• EGFR kinase inhibitor combinations for treating respiratory and gastrointestinal disorders
  申请人：Boehringer Ingelheim International GmbH

  公开号：EP2116245A2

  公开（公告）日：2009-11-11

  The present invention relates to novel pharmaceutical compositions comprising at least one EGFR kinase inhibitor and at least one additional active compound selected from beta-2 mimetics, steroids, PDE-IV inhibitors, p38 MAP kinase inhibitors, NK1 antagonists and endothelin-antagonists, processes for preparing the compositions and the use thereof as medicament in the treatment of respiratory or gastrointestinal complaints, as well as inflammatory diseases of the joints, the skin or the eyes.

  本发明涉及新型药物组合物，该组合物包含至少一种表皮生长因子受体激酶抑制剂和至少另外一种选自β-2模拟物、类固醇、PDE-IV抑制剂、p38 MAP激酶抑制剂、NK1拮抗剂和内皮素拮抗剂的活性化合物；本发明还涉及组合物的制备工艺及其在治疗呼吸道或胃肠道疾病以及关节、皮肤或眼睛炎症性疾病中的用途。